Terry Lemerond, founder of Enzymatic Therapy, EuroPharma, and Terry Naturally, has been a leader in introducing novel ingredients to the market for decades. While red Asian ginseng is not a new ingredient, EuroPharma has introduced to the market a proprietary extract made form hydroponically cultivated roots that consistently produces a profile and ratio of special ginsenosides, sometimes referred to as “noble ginsenosides,” while avoiding the issues of poor quality, pesticides, adulteration, and inconsistency that plagues the ginseng market. According to Lemerond, the introduction of this novel extract “is a game changer for the world of ginseng products.”
According to Roy Upton, AHP president, “Terry has always been a leader in many aspects of the natural products industry and has always been at the forefront of bringing new products to the market and educating customers about them. We are excited to see what the new generation of ginseng ingredients has to offer.”
While the monograph will provide a comprehensive review of red Asian ginseng overall, specifics regarding the different preparations available will be presented. Due to its relatively high expense, red Asian ginseng is one of the most commonly adulterated botanicals on the market and is sorely in need of more education to guide manufacturers in navigating the ginseng market.
Lemerond stated, “I’m very happy to support the work of AHP both financially and technically with the help of our scientists. Roy Upton and his associates have done a remarkable job providing substantiation of botanical medicines one monograph at a time. Healthcare in the United States is driven by drug therapy. Sixty percent of all the drugs manufactured worldwide are prescribed in America. Eighty percent of the world’s population depends on plant medicines. AHP provides the necessary documentation to educate professionals and the general population to help close that gap.”